RecruitingN/AOther

The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA)

NCT ID

NCT06707532

Target Enrollment

32 participants

Start Date

2024-08-01

Est. Completion

2025-12-01

About This Study

The study aims to improve the safety of the electroporation ablation (PFA) procedure by using muscle relaxants to reduce skeletal muscle damage during the procedure. It will also assess myocardial damage to improve the procedure's quality and speed up recovery after the procedure.

Conditions Studied

Kidney Failure, AcuteMyopathy; DrugsHeart ArrhythmiaSuccinylcholine SensitivityMuscle RelaxationGeneral Anesthetic Drug Adverse ReactionProjection

Interventions

•Propofol
•Rocuronium

Eligibility

Age:18 Years - 90 Years

Healthy Volunteers:No

View full eligibility criteria

Inclusion Criteria:

* Patients with requirement for PFA ablation for cardiac indications and ability to provide informed consent for study participation

Exclusion Criteria:

* Patients with allergies to the general anaesthetics used, genetic diseases of the neuromuscular plateau - e.g. Duchenne dystrophy, myasthenia gravis - and patients who do not gived informed consent to participate in the study will be excluded from the study.

Study Locations (1)

4th Military Clinical Hospital with Polyclinic